Abstract:Background Cancer immunotherapies can induce durable tumor regression, but most patients do not respond. SETD2 mutation has been linked to the efficacy of immune checkpoint inhibitors (ICIs) immunotherapy. The functional importance of the SETD2 inactivation and how to modulate immunotherapy response remains unclear. Methods To explore the function of SETD2 in immunotherapy, knockout and subsequent functional experiments were conducted. Bulk RNA-seq, ATAC-seq, Chip-seq and single-cell RNA-seq were performed to dissect the mechanism and explore the immune microenvironment of mouse tumor. Flow cytometry was used to assess cell surface antigen and intratumoral T cell levels. Results We comprehensively determine the effect of SETD2 inactivation in ICIs therapy and elucidate the mechanistic impact on tumor immunity. Murine syngeneic tumors harboring Setd2 inactivation are sensitive to ICIs. By bulk and single-cell RNA-seq, we further reveal that SETD2 inactivation reprograms intratumoral immune cells and inflames the tumor microenvironment, which is characterized by high infiltration of T cells and enhanced antigen presentation to activate CD8 + T cell-mediated killing. Mechanistically, via an integrated multiomics analysis using ATAC-seq, ChIP-seq and RNA-seq, we demonstrate that SETD2 inactivation reduces NR2F1 transcription by impairing H3K36me3 deposition and chromatin accessibility, which activates the STAT1 signaling pathway to promote chemokines and programmed cell death protein-1 (PD-1) expression and enhance antigen presentation. All these regulatory mechanisms synergistically promote the effects of anti-programmed cell death ligand 1 immunotherapy in Setd2 -knockout syngeneic mouse models. The SETD2-NR2F1-STAT1 regulatory axis is conserved in human and murine cancers. Finally, cancer patients harboring SETD2 mutations who received ICIs show increased durable clinical benefits and survival. Conclusions These findings provide novel insights into the biology of SETD2 inactivation regulation and reveal a new potential therapeutic biomarker for ICIs immunotherapy in various refractory cancers.

Role of histone methyltransferase SETDB1 in regulation of tumourigenesis and immune response.

Targeting the Tumor Epigenetic Regulator SETDB1 for Tumor Therapy

The function of histone methyltransferase SETDB1 and its roles in liver cancer

Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity

SETDB1, an H3K9-specific methyltransferase: An attractive epigenetic target to combat cancer

Histone Methyltransferase SETDB1 Promotes Immune Evasion in Colorectal Cancer via FOSB-Mediated Downregulation of MicroRNA-22 through BATF3/PD-L1 Pathway.

Histone Methyltransferase SETD2: a Potential Tumor Suppressor in Solid Cancers

Histone Methyltransferase SETDB1 Regulates Liver Cancer Cell Growth Through Methylation of P53

Blocking histone methyltransferase SETDB1 inhibits tumorigenesis and enhances cetuximab sensitivity in colorectal cancer

KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements

Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer

Histone Methyltransferase SETDB1 Promotes Colorectal Cancer Proliferation Through the STAT1-CCND1/CDK6 Axis.

Oncogene or Tumor Suppressor: The Coordinative Role of Lysine Methyltransferase SET7/9 in Cancer Development and the Related Mechanisms

H3K36 trimethylation-mediated biological functions in cancer

Histone methyltransferase SETD2: An epigenetic driver in clear cell renal cell carcinoma

High SET Domain Bifurcated 1 (SETDB1) Expression Predicts Poor Prognosis in Breast Carcinoma

Setdb1 Accelerates Tumourigenesis by Regulating the Wnt Signalling Pathway

SETDB1 promotes the progression of colorectal cancer via epigenetically silencing p21 expression

SETDB1 Restrains Endogenous Retrovirus Expression and Antitumor Immunity during Radiotherapy

Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway

Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential